On this week’s episode of “The Readout LOUD”: The Food and Drug Administration’s AI adventure, a deep look inside Novo Nordisk’s obesity stumble, and finally, another big M&A deal in biotech.

The FDA has rolled out an internal AI tool called Elsa that, unlike its namesake Disney character, can’t seem to let go of mistakes. Our colleague Brittany Trang joins to explain. And it’s always a fun podcast when we can discuss a biotech acquisition. This week, we’ll chat about Sanofi’s $9 billion offer for Blueprint Medicines.

But first, Novo Nordisk was once the leader in the obesity drug race. Today, it trails Eli Lilly. Our co-host Elaine Chen has a new story published this week that examines the reasons behind Novo’s fall and what it’s doing to catch up. You’ll hear all about it.

Be su

See Full Page